false
0000883975
0000883975
2025-10-14
2025-10-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 14, 2025
MICROBOT
MEDICAL INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
000-19871 |
|
94-3078125 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
175
Derby St., Bld. 27
Hingham,
MA 02043
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (781) 875-3605
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, $0.01 par
value |
|
MBOT |
|
NASDAQ Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
October 14 2025, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has partnered with a U.S.
based third-party logistics company to support the commercialization of its FDA-cleared LIBERTY® Endovascular Robotic
System.
The
press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information
in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be
deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.
Item
8.01 Other Events.
The
Company partnered with a U.S. based third-party logistics (3PL) company to support the commercialization of its FDA-cleared LIBERTY®
Endovascular Robotic System. The Company is expected to initiate the limited market release of the LIBERTY® System during
the fourth quarter of 2025 with the broader launch anticipated to occur in April 2026 during the Society of Interventional Radiology
conference.
Forward
Looking Statements
This
Item 8.01 of this Current Report on Form 8-K may contain “forward-looking statements.” Such statements which are not purely
historical (including, but not limited to statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “intends,” “would,” “could” and “estimates”)
are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future,
including but not limited to, regulatory milestones.
Actual
results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements
are made as of the date of this Form 8-K, and the Company assumes no obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Although
the Company believes that the beliefs, plans, expectations and intentions contained in this Form 8-K are reasonable, there can be no
assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information
set forth herein and should also refer to the risk factors disclosure outlined in the Company’s reports and statements filed from
time-to-time with the Securities and Exchange Commission.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number |
|
Description |
| |
|
|
| 99.1 |
|
Press Release |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
| |
MICROBOT MEDICAL INC. |
| |
|
| |
By: |
/s/
Harel Gadot |
| |
Name: |
Harel Gadot |
| |
Title: |
Chief Executive Officer, President and Chairman |
Date:
October 14 2025
